Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety
Page 1 of 1
Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety
Jon Moulton Fri Sep 05, 2014 2:47 pm
Mendell JR, Rodino-Klapac L, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Malik V, Shontz K, Flanigan KM, Shilling C, Sazani P, Saoud J, Duda P, Kaye E. G.O.24: Eteplirsen in Duchenne Muscular Dystrophy (DMD): 3 year update on Six-Minute Walk Test (6MWT) and Safety. Neuromusc Disorders. 2014;24(9):922. doi:10.1016/j.nmd.2014.06.423
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 61
Location : Philomath, Oregon, USA -
Similar topics» Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for the Treatment of Duchenne Muscular Dystrophy (DMD): 168 Week Update on Six-Minute Walk Test (6MWT), Pulmonary Function Testing (PFT), and Safety
» Safety and pharmacokinetic profile of eteplirsen, SRP-4045, and SRP-4053, three phosphorodiamidate morpholino oligomers (PMOs) for the treatment of patients with Duchenne muscular dystrophy (DMD)
» Eteplirsen for the treatment of duchenne muscular dystrophy
» Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production
» Exon Skipping Quantification by qRT-PCR in Duchenne Muscular Dystrophy Patients Treated with the Antisense Oligomer Eteplirsen
» Safety and pharmacokinetic profile of eteplirsen, SRP-4045, and SRP-4053, three phosphorodiamidate morpholino oligomers (PMOs) for the treatment of patients with Duchenne muscular dystrophy (DMD)
» Eteplirsen for the treatment of duchenne muscular dystrophy
» Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production
» Exon Skipping Quantification by qRT-PCR in Duchenne Muscular Dystrophy Patients Treated with the Antisense Oligomer Eteplirsen
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum|
|
|